Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study - Concepedia

Concepedia

Publication | Open Access

Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study

DOI Full Paper Access

11

Citations

15

References

2023

Year

Afisi Ismaila, Kieran Rothnie, Robert Wood, Victoria Banks, Lucinda Camidge, Alexandrosz Czira, Chris Compton, Raj Kumar Sharma, Shannon N. Millard, Olivia Massey,

Respiratory Research

Abstract

Prompt initiation of FF/UMEC/VI following a moderate/severe exacerbation was associated with fewer subsequent exacerbations, fewer hospital readmissions, and lower COPD-related medical costs compared with delayed initiation.

References

	Year	Citations
Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD David A. Lipson, Frank Barnhart, Noushin Brealey, New England Journal of Medicine	2018	1.2K
Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum Achim Wolf, Daniel Dedman, Jennifer Campbell, International Journal of Epidemiology	2019	837
Validation of the Recording of Acute Exacerbations of COPD in UK Primary Care Electronic Healthcare Records Kieran Rothnie, Hana Müllerová, John R. Hurst, PLoS ONE	2016	167
Recording of hospitalizations for acute exacerbations of COPD in UK electronic health care records Kieran Rothnie, Hana Müllerová, Sara L. Thomas, Clinical Epidemiology	2016	95
<p>Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population</p> Michael Bogart, Richard H. Stanford, François Laliberté, International Journal of COPD	2019	91
INTREPID: single-<i>versus</i>multiple-inhaler triple therapy for COPD in usual clinical practice David Halpin, Sally Worsley, Afisi Ismaila, ERJ Open Research	2021	63
Impact of COVID-19 on COPD and asthma admissions, and the pandemic from a patient's perspective Dominic L. Sykes, Shoaib Faruqi, Luke Holdsworth, ERJ Open Research	2020	51
Comparative Adherence and Persistence of Single- and Multiple-Inhaler Triple Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care Setting David Halpin, Kieran Rothnie, Victoria Banks, International Journal of COPD	2022	44
<p>Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial</p> Afisi Ismaila, Nancy Risebrough, Melanie Schroeder, International Journal of COPD	2019	35
Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Following a COPD Exacerbation David M. Mannino, Michael Bogart, Guillaume Germain, International Journal of COPD	2022	27

Page 1